Global Cell and Gene Therapy CDMO Market Anticipating Remarkable Growth at a CAGR of ~24% by 2034 | DelveInsight

The cell and gene therapy CDMO market is experiencing significant growth, driven by the increasing number of cell and gene therapy candidates advancing through clinical development and commercialization. Rising investments in regenerative medicine, CAR-T therapies, gene editing technologies, and rare disease treatments are fueling demand for specialized manufacturing services. Pharmaceutical and biotechnology companies are increasingly partnering with CDMOs to access advanced manufacturing capabilities, reduce production costs, and accelerate time-to-market. Additionally, ongoing technological advancements in viral vector production, cell processing, and scalable manufacturing platforms are further supporting market expansion. As the CGT pipeline continues to mature globally, the need for experienced CDMO partners is expected to grow substantially over the coming years.

New York, USA, June 18, 2026 (GLOBE NEWSWIRE) -- Global Cell and Gene Therapy CDMO Market Anticipating Remarkable Growth at a CAGR of ~24% by 2034 | DelveInsight

The cell and gene therapy CDMO market is experiencing significant growth, driven by the increasing number of cell and gene therapy candidates advancing through clinical development and commercialization. Rising investments in regenerative medicine, CAR-T therapies, gene editing technologies, and rare disease treatments are fueling demand for specialized manufacturing services. Pharmaceutical and biotechnology companies are increasingly partnering with CDMOs to access advanced manufacturing capabilities, reduce production costs, and accelerate time-to-market. Additionally, ongoing technological advancements in viral vector production, cell processing, and scalable manufacturing platforms are further supporting market expansion. As the CGT pipeline continues to mature globally, the need for experienced CDMO partners is expected to grow substantially over the coming years.

DelveInsight’s Cell and Gene Therapy CDMO Market Insights report provides the current and forecast market analysis, individual leading Cell and Gene Therapy CDMO companies’ market shares, challenges, Cell and Gene Therapy CDMO market drivers, barriers, trends, and key Cell and Gene Therapy CDMO companies in the market.

Cell and Gene Therapy CDMO Market Summary

• 2025 Cell and Gene Therapy CDMO Market Size: USD 8.3 Billion
• 2034 Projected Cell and Gene Therapy CDMO Market Size: USD 57.1 Billion
• Cell and Gene Therapy CDMO Market Growth Rate (2026-2034): ~24% 
• Largest Cell and Gene Therapy CDMO Market: North America
• Largest Product Type Segment: Cell and Gene Therapy Category
• Key Companies in the Cell and Gene Therapy CDMO Market: Catalent, Inc., Minaris Advanced Therapies, SCTbio, a.s., Cellex Cell Professionals GmbH, Mycenax Biotech Inc., MedTherapy Biotech, ENCELL Co., Ltd., Nucelion Biotechnologies, Charles River Laboratories International, Inc., Lonza Group AG, Thermo Fisher Scientific ., WuXi AppTec Co., Ltd., and others

To read more about the latest highlights related to the Cell and Gene Therapy CDMO market, get a snapshot of the key highlights @ https://www.delveinsight.com/sample-request/cell-and-gene-therapy-cdmo-market

Key Factors Contributing to the Rise in Growth of the Cell and Gene Therapy CDMO Market

• Rising Number of Cell and Gene Therapy Candidates: The expanding pipeline of gene therapies, CAR-T therapies, stem cell therapies, and gene-editing products has significantly increased the demand for specialized manufacturing and development services offered by CDMOs.
• Growing Outsourcing Trends Among Biopharma Companies: Many biotechnology and pharmaceutical companies prefer outsourcing manufacturing to CDMOs to reduce capital expenditure, accelerate development timelines, and access specialized expertise.
• Complexity of Cell and Gene Therapy Manufacturing: Advanced therapies require highly specialized production processes, stringent quality controls, and sophisticated facilities, making CDMOs valuable partners for efficient product development and commercialization.
• Increasing Clinical Trial Activity: The growing number of clinical trials evaluating novel cell and gene therapies is driving demand for process development, analytical testing, and GMP manufacturing services throughout the development lifecycle.
• Advancements in Manufacturing Technologies: Innovations such as automated bioprocessing, closed-system manufacturing, digital monitoring, and AI-driven process optimization are improving scalability and efficiency, encouraging greater CDMO utilization.
• Expansion of Commercial Manufacturing Requirements: As more cell and gene therapies receive regulatory approvals, developers increasingly rely on CDMOs to support large-scale commercial production and global product supply.
• Growing Investment in Regenerative Medicine: Rising public and private investments in regenerative medicine, gene editing, and personalized therapies are fueling the development of new products and increasing demand for specialized manufacturing partners.
• Stringent Regulatory and Quality Compliance Needs: Regulatory agencies require robust manufacturing standards and quality systems for advanced therapies. Established CDMOs provide regulatory expertise and compliance capabilities that help reduce development risks.
• Increasing Demand for End-to-End Service Offerings: Sponsors are seeking integrated solutions covering process development, analytical testing, clinical manufacturing, regulatory support, and commercial production, driving growth for full-service CDMOs.

Get a sneak peek at the Cell and Gene Therapy CDMO market dynamics @ Cell and Gene Therapy CDMO Market Trends

Regional Cell and Gene Therapy CDMO Market Insights

North America

• North America held the largest share of the cell and gene therapy CDMO market, accounting for approximately 40% of the global market in 2025. 
• Market growth in the region is primarily fueled by the expanding pipeline of cell and gene therapies, increasing adoption of personalized treatment approaches, and substantial investments in innovative therapeutic technologies. 
• With a well-established biotechnology ecosystem, advanced healthcare infrastructure, and favorable regulatory support, North America has emerged as a key center for the development of CAR-T cell therapies, stem cell-based treatments, gene-editing platforms, and viral vector technologies. 
• Furthermore, the rising number of therapies being developed for oncology, rare genetic diseases, autoimmune disorders, and neurological conditions is driving demand for outsourced services, including process development, analytical testing, clinical-scale manufacturing, and commercial production.

Europe

• The European cell and gene therapy CDMO market is experiencing robust growth, driven by a mature biotechnology landscape, a rising number of preclinical and clinical-stage therapy candidates, a strong foundation in academic research, and favorable regulatory support. 
• Key markets, including the UK, Germany, and France, have established themselves as major centers for advanced therapy innovation, benefiting from close partnerships among research institutions, biotechnology companies, and CDMOs. 
• The expanding pipeline of cell and gene therapies for oncology, rare diseases, and inherited genetic conditions is fueling the need for specialized outsourced development and manufacturing capabilities throughout the region. 
• Furthermore, the presence of prominent CDMOs, along with ongoing investments in viral vector production capacity and advanced cell therapy technologies, continues to enhance the growth prospects of the European market.

Asia-Pacific

• The Asia-Pacific region is becoming a significant contributor to the growth of the cell and gene therapy CDMO market, driven by rising investments in biotechnology, expanding healthcare infrastructure, and an increasing volume of clinical research activities. 
• The growing adoption of advanced treatment modalities, including CAR-T therapies, gene therapies, and stem cell-based treatments, is further fueling demand for specialized development and manufacturing services. 
• Key markets such as China, Japan, South Korea, and India are strengthening their biomanufacturing ecosystems, offering cost-effective operations and access to a highly skilled talent pool, which continues to attract global biopharmaceutical companies.
• Moreover, favorable government policies, evolving regulatory environments, and the emergence of regional CDMOs are enhancing the outsourcing landscape across the region. 
• These factors, combined with increasing innovation and production capabilities, position APAC as a strategic hub and a major growth engine for the future expansion of the Cell and Gene Therapy CDMO market.

To know more about why North America is leading the market growth in the Cell and Gene Therapy CDMO market, get a snapshot of the Cell and Gene Therapy CDMO Market Share

Recent Developmental Activities in the Cell and Gene Therapy CDMO Market

• In April 2026, Catalent, Inc. expanded its commercial licensing agreement with Cartherics to support the manufacturing and commercialization of iPSC-derived CAR-NK cell therapies for cancer treatment, strengthening its position in advanced cell therapy manufacturing.
• In March 2026, Lonza expanded its commercial manufacturing agreement with Genetix Biotherapeutics for the production of the gene therapy ZYNTEGLO™, reflecting increasing commercial demand for gene therapy manufacturing services.
• In March 2026, Catalent partnered with GelMEDIX for the development and clinical manufacturing of iPSC-derived therapies for ocular and retinal diseases, strengthening early-stage cell therapy manufacturing capabilities in North America.
• In February 2026, Oxford Biomedica signed a new multi-year commercial supply agreement with Bristol Myers Squibb to manufacture lentiviral vectors for CAR-T programs, reinforcing Europe’s role in commercial-scale gene therapy manufacturing.

What is a Cell and Gene Therapy CDMO?

A cell and gene therapy Contract development and manufacturing organization (CGT CDMO) is a specialized service provider that supports biotechnology and pharmaceutical companies in the development, manufacturing, testing, and commercialization of cell and gene therapy products. These organizations offer end-to-end capabilities, including process development, viral vector production, cell processing, analytical testing, regulatory support, and large-scale manufacturing under Good Manufacturing Practice (GMP) standards. As cell and gene therapies are highly complex and require specialized infrastructure, expertise, and stringent quality controls, many developers partner with CDMOs to accelerate development timelines, reduce capital investments, and ensure scalable production. The growing pipeline of advanced therapies and increasing demand for commercial manufacturing capacity have made CGT CDMOs a critical component of the cell and gene therapy ecosystem.

Cell and Gene Therapy CDMO Market Assessment

• Cell and Gene Therapy CDMO Market Segmentation
  • Cell and Gene Therapy CDMO Market Segmentation By Product Type: Cell Therapy, Gene Therapy, and Gene-Modified Cell Therapy
  • Cell and Gene Therapy CDMO Market Segmentation By Service Type: Process Development Services, Manufacturing Services, and Others
  • Cell and Gene Therapy CDMO Market Segmentation By Development Phase: Pre-clinical Phase, Clinical Phase, and Commercial Manufacturing
  • Cell and Gene Therapy CDMO Market Segmentation By Indication: Oncology, Rare Diseases, and Others
  • Cell and Gene Therapy CDMO Market Segmentation By End Users: Biopharmaceutical Companies, Biotechnology Startups, and Academic & Research Institutes
  • Cell and Gene Therapy CDMO Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the Cell and Gene Therapy CDMO market are set to emerge as the trendsetter explore @ Cell and Gene Therapy CDMO Market Analysis

Table of Contents 

Interested in knowing the Cell and Gene Therapy CDMO market share by 2034? Click to get a snapshot of the Cell and Gene Therapy CDMO Market Size 

Related Reports

Cell and Gene Therapy Manufacturing Market

Cell and Gene Therapy Manufacturing Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key CGT manufacturing companies, including Lonza, Catalent, Inc., Thermo Fisher Scientific , Inc., Charles River Laboratories, WuXi AppTec, Merck KGaA KGaA, Takara Bio Inc., Oxford Biomedica PLC, Genezen, FUJIFILM Holdings Corporation, Nikon Corporation, The Discovery Labs LLC, RoslinCT, JRS Pharma, FinVector, Sarepta Therapeutics, Inc., BioCentriq, Andelyn Biosciences, ElevateBio, Anemocyte Srl, and others.

Gene Therapy Market

Gene Therapy Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key gene therapy companies, including F. Hoffmann-La Roche Ltd., Novartis AG, Ferring B.V., bluebird bio, Inc., CSL, Ultragenyx Pharmaceutical Inc., PTC Therapeutics, BioMarin, Biogen , Prevail Therapeutics, Sarepta Therapeutics, Inc., Kriya Therapeutics, Affinia Therapeutics, Caribou Biosciences, Pfizer ., and others.

Contract Development Manufacturing Organization Market

Contract Development Manufacturing Organization Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key CDMO companies such as Catalent Inc., Thermo Fisher Scientific ., The Lubrizol Corporation, Recipharm ( EQT ), Cambrex Corporation, Merck KGaA & Co. Inc., AGC Biologics, Nerpharma S.r.l., Danaher Corporation, EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Revvity Inc., WuXi Biologics, Laboratoire Elaiapharm, and others.

Viral Vector CDMO Market

Viral Vector CDMO Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key viral vector CDMO companies such as Lonza Group, Thermo Fisher Scientific , Catalent, Oxford Biomedica, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, WuXi AppTec, Merck KGaA KGaA, AGC Biologics, Takara Bio, Samsung Biologics, Curia Global, GenScript ProBio, Creative Biogene, VectorBuilder, Aldevron, FinVector, Yposkesi, VGXI, Genezen, and others.

Viral Vector Manufacturing Market 

Viral Vector Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key viral vector manufacturing companies such as Oxford Biomedica, Thermo Fisher Scientific ., Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Batavia Biosciences, CEVEC Pharmaceuticals GmbH, REGENXBIO Inc., BioNTech IMFS, AGC Biologics, ANDELYN BIOSCIENCES, INSTITUT MERIEUX, IDT Biologika, Lonza, Genezen, NecstGen, Avid Bioservices, Inc., Takara Bio Inc., VIROCELL BIOLOGICS, LTD., and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679